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ORIGINAL ARTICLE
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Summary
Aims: Hyperbaric oxygen therapy (HBOT) has been widely used as postinjury treat‐
ment; however, we investigate its ability to mitigate potential damage as a precondi‐
tioning option. Here, we tested the hypothesis that HBOT preconditioning mitigates
cell death in primary rat neuronal cells (PRNCs) through the transfer of mitochondria
from astrocytes.
Methods: Primary rat neuronal cells were subjected to a 90‐minute HBOT treatment
at 2.5 absolute atmospheres prior to either tumor necrosis factor‐alpha (TNF‐alpha)
or lipopolysaccharide (LPS) injury to simulate the inflammation‐plagued secondary
cell death associated with stroke and traumatic brain injury (TBI). After incubation
with TNF‐alpha or LPS, the cell viability of each group was examined.
Results: There was a significant increase of cell viability accompanied by mitochon‐
drial transfer in the injury groups that received HBOT preconditioning compared to
the injury alone groups (44 ± 5.2 vs 68 ± 4.48, n = 20, P < 0.05). The transfer of mito‐
chondria directly after HBOT treatment was visualized by capturing images in 5‐min‐
ute intervals, which revealed that the robust transfer of mitochondria begins soon
after HBOT and persisted throughout the treatment.
Conclusion: This study shows that HBOT preconditioning stands as a robust prophy‐
lactic treatment for sequestration of inflammation inherent in stroke and TBI, possi‐
bly facilitating the transfer of resilient mitochondria from astrocytes to
inflammation‐susceptible neuronal cells in mitigating cell death.
KEYWORDS

hyperbaric, mitochondria transfer, preconditioning, stroke, traumatic brain injury

1 | I NTRO D U C TI O N

130 000 each year. The associated healthcare costs for stroke ex‐
ceed $33 billion per year. Stroke is the leading cause of long‐term

Central nervous systems (CNS) diseases encompass a wide variety

disability in the United States. 2 Comparably, in 2013, TBI resulted in

of pathologies. However, stroke and traumatic brain injury (TBI)

2.8 million emergency room visits, hospitalizations, and deaths, ac‐

are the most prevalent neurodegenerative diseases of adult‐brain

companying the approximately 3.1 million people living with TBI‐re‐

1

lated diseases, with an associated healthcare cost of $76.5 billion in

According to the American Heart Association, stroke is the fifth‐

2012.3,4 Stroke and TBI share some similar pathologies regarding the

leading cause of death in the United States, killing approximately

primary and secondary cell death mechanism largely resulting from

1

in the United States, which can strike a wide spectrum of people.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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chronic neuroinflammation.5 A key common pathological feature is

neuronal cells was also examined.35 We hypothesized that a transfer

the formation of a necrotic tissue core, which is unrecoverable, fol‐

of astrocytic mitochondria into neurons, following HBOT precondi‐

lowing stroke and TBI.6-8 The onset and progression of secondary

tioning, would improve neuronal cell viability following inflammatory

cell death of both diseases has been linked to the blood‐brain barrier

insults.

(BBB) breakdown, allowing various inflammatory cytokines to per‐
meate the BBB, infiltrate the brain, and upregulate the inflammatory
response,9 altogether worsening the disease outcomes. In addition,
several other exacerbating factors, such as oxidative stress, apopto‐
sis, and mitochondrial dysfunction, have been shown to contribute
to additional neurodegeneration following BBB damage.10-13

2 | M ATE R I A L S A N D M E TH O DS
2.1 | Cell culture
The research procedures involving animals were approved by the

Hyperbaric oxygen therapy (HBOT) has been a treatment of in‐

USF Institutional Animal Care and Use Committee (IACUC). Primary

terest for stroke as well as TBI over the past decade.14,15 HBOT uti‐

rat neuronal cells (PRNCs) were dissected from cerebral cortices of

lizes a pressurized chamber, usually 2‐3 absolute atmospheres (ATA),

E18 Sprague‐Dawley rat embryos. Cells were seeded on poly‐D‐ly‐

resulting in hyperoxygenation of tissues, inducing local angiogenesis

sine (Fisher Scientific, ICN10269480) coated glass coverslips in 6‐

in damaged regions of the body and recruitment of progenitor cells

well plates (Fisher Scientific, 0877124) and cultured in Dulbecco's

to the damaged regions.16-18 The common, FDA‐approved, uses of

Modified Eagle Media (DMEM, Fisher Scientific, 10567‐014) con‐

HBOT include treating patients with open wounds, often resulting

taining 4.5 g/L glucose, l‐glutamine, 25 mmol/L HEPES, 10% fetal

19,20

The ability for a patient to

bovine serum (FBS, Fisher Scientific, SH3007103) and 1% antibiotic/

undergo HBOT during the acute stage of stroke has been difficult to

antimycotic at a density of 1.5 × 106 cells per well. After 24 hours,

accomplish due to the overall timeline of the ischemic event and a

the medium was changed to Neurobasal medium (Fisher Scientific,

limited number of facilities having the necessary equipment; there‐

21103049), supplemented with B‐27 (Fisher Scientific, 17504044).

fore, the chronic stages of stroke have been targeted as a possible

Cells were cultured in incubator at 37°C with 5% CO2. Cells were

from burn injuries or diabetic ulcers.

therapeutic window for HBOT.14 This regimen seeks to ameliorate

utilized for experiments 7 days after seeding. Astrocytes derived

cognitive impairments synonymous with stroke, such as memory

from U‐87 MG Astrocyte Cell Line (Sigma, 89081402). The cells

loss, language and comprehension deficits.14,21 Similarly, the unfore‐

were passaged six times for growth in T‐175 flasks (Fisher Scientific,

seen occurrence of TBI presents as a logistical hurdle in introducing

12562001) in DMEM with 10% FBS and 1% penicillin/streptomycin

HBOT as an acute treatment regimen for brain trauma patients. 22

(Fisher Scientific, 15140122). One day prior to coculture, the astro‐

Mechanistically, the secondary cell death with wider therapeutic

cytes were seeded on a 0.4 μm mesh plate insert (Fisher Scientific,

window, characterized by inflammation has become the main target

0877115) in DMEM with 10% FBS and 1% penicillin/streptomycin

of HBOT treatment research, as reducing the levels of inflammatory

at a density of 3 × 105 cells per well. On day 7 postseeding, the

cytokines has been linked to limiting peri‐infarct/peri‐impact tissue

astrocyte mesh inserts were placed in coculture with the PRNCs

loss. 23,24 However, the therapeutic mechanism of HBOT mediating

(Figure 1).

the sequestration of inflammation is not fully understood. 25
A key unexplored research theme in the use of HBOT as a treat‐
ment for stroke and TBI involves investigations into the role of the

2.2 | HBOT

preconditioning paradigm. Several studies have shown the preclini‐

Hyperbaric oxygen therapy was administered using an OxyCure

cal efficacy of HBOT preconditioning for attenuating neuronal cell

3000 hyperbaric incubator (OxyHeal Health Group, National City,

loss following an ischemic or traumatic event, but little mechanism‐

CA, USA). The HBOT regimen consisted of a single treatment at 2.5

based assessment has elucidated the therapeutic pathways solicited

absolute atmospheres lasting 90 minutes, with a 10‐minute ascent

by HBOT in these studies. 26-29 The importance of alternative thera‐

and descent period (Figure 2). Following HBOT the cultures were

pies for stroke and TBI patients has become evident.30 To this end,

returned to an incubator at 37°C and 5% CO2. Cultures remained in

cognizant that mitochondrial dysfunction closely approximates a

incubation for 24 hours prior to insult.

pathologic inflammatory response resulting from ischemia and trau‐
matic insult, evaluation of the mitochondria poses as a logical target
of investigation in order to begin to understand the mechanism of

2.3 | Injury

HBOT preconditioning.31-33 Of note, healthy extracellular mitochon‐

To recreate the secondary cell death of inflammation observed in

dria have been demonstrated to transfer from astrocytes into neu‐

stroke and TBI, we employed two established inflammation‐induc‐

rons following stroke resulting in reduced neuronal cell death.34

ing agents.36-38 The tumor necrosis factor‐alpha (TNF‐alpha, Fisher

In this study, we explored the ability of HBOT preconditioning to

Scientific, 210TA020CF) only and HBOT plus TNF‐alpha cocultures

limit neuronal cell death following inflammatory insults, mimicking

were treated with 50 ng/mL of TNF‐alpha (RD) for 24 hours39 in the

the secondary cell death associated with ischemic stroke and TBI.

incubator at 37°C and 5% CO2. The Lipopolysaccharide (LPS, Fisher

More importantly, the potential role of HBOT in transferring mito‐

Scientific, NC0202558) injury and HBOT plus LPS groups were

chondria as a therapeutic mechanism in facilitating survival of the

treated with 100 ng/mL of LPS and returned to the incubator.40 Each

|
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F I G U R E 1 Experimental design. Timeline of experiment, including cell culture and immunocytochemistry. Hyperbaric oxygen
preconditioning in vitro treatment. Astrocytes stained with Mitotracker are cocultured on top of E18 primary cortical neurons (PRNCs) in a
growth medium. The cocultured plates were then placed in a hyperbaric oxygen chamber for treatment. Mitotracker of astrocytes was found
in the primary E18 cortical neurons

F I G U R E 2 Hyperbaric oxygen therapy
course. Pressure graph of hyperbaric
oxygen preconditioning. During the first
10 min, there is a constant increase of
pressure until the chamber reaches 49.5
feet of seawater (FSW). This pressure
is sustained for 70‐min, followed by a
constant depressurization of the chamber
over a 10‐min period. The total length of
the preconditioning treatment is 90 min

insult used the same medium as previously described for neurons
and astrocytes. The control plates remained untreated.

images were captured per well in randomly selected regions to
determine cell viability at 10×. Analysis of cell intensity was per‐
formed by ImageJ (NIH). During cell counting, 30.25 cm2 regions

2.4 | Measurement of cell viability
After the 24‐hour incubation with TNF‐alpha and LPS, all groups

were counted using ImageJ and calculated to determine the number
of cells per 1 cm2. Analysis of data was conducted using GraphPad
Prism 6 (GraphPad Software, La Jolla California USA).

were assessed for cell viability using calcein‐AM (Fisher Scientific,
4892010K). After treatment, the astrocyte mesh inserts were re‐
moved and the remaining 6‐well dish was incubated with 1 μmol/L

2.5 | Immunocytochemistry

calcein‐AM for 30 minutes in the incubator at 37°C with 5% CO2.

Prior to coculturing neurons and astrocytes, each was labeled with

Bright green fluorescence was retained within living cells. Five

mitotracker, in order to visualize mitochondria belonging to each

818
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cell type. Astrocytes were labeled with Mitotracker Deep Red FM
(Fisher Scientific, M22426) for 30 minutes in DMEM with 10%
FBS and 1% penicillin/streptomycin (Fisher Scientific, 15‐140‐122)
with 500 nmol/L of Mitotracker Deep Red. Neurons were labeled
with Mitotracker Green FM (Fisher Scientific, M7514) for 30 min‐
utes in Neurobasal with B‐27 supplement at 37°C and 5% CO2 .
Following HBOT and insult, cells were rinsed with Dulbecco's
phosphate‐buffered saline with calcium and magnesium (DPBS,
Fisher Scientific, 14080055) and then fixed with 4% paraform‐
aldehyde (PFA) for 20 minutes at room temperature. Cells were
rinsed again with DPBS. Cultures were permeabilized with 0.3%
Triton‐X for 5 minutes at room temperature. Plates were rinsed
with DPBS before blocking with 5% goat serum at room tem‐
perature. Mouse anti‐MAP2 1 μg/mL was added to each well
and incubated overnight at 4°C. After rinsing several times with
DPBS, Alexa Fluor 488 goat anti‐mouse 1 μg/mL was added and
incubated for 60 minutes at room temperature. Plates were then
rinsed with DPBS, and coverslips were placed on slides using
Vectashield with 4,6‐diamidino‐2‐phenylindole DAPI (Fisher
Scientific, NC9524612). Immunostaining images were captured
using an Olympus FV1200 Spectral Inverted Laser Scanning
Confocal Microscope. Colocalizations of astrocytic mitochondria
with PRNCs as well as with endogenous mitochondria from PRNCs
were assessed.

LIPPERT and BORLONGAN

3 | R E S U LT S
3.1 | Hyperbaric oxygen treatment rescues cell
viability
Calcein‐AM cell viability staining was performed and imaged using
a fluorescent inverted microscope (Figure 3). Cell viability of E18
cortical neurons cocultured with U‐87 astrocytes was measured via
cell counting of neurons and intensity of calcein staining. Control
E18 cortical neurons had an average of 7.11 cells per 1 cm2 and an
average intensity of 4290. E18 cortical neurons exposed only to
HBOT had an average of 7.15 cells per 1 cm2 and an average inten‐
sity of 3744. Cortical neurons administered TNF‐alpha had an aver‐
age of 5.60 cells per 1 cm2 and an average intensity of 1507, while
cortical neurons administered LPS had an average of 3.56 cells
per 1 cm2 and an average intensity of 2025. The cortical neurons
exposed to HBOT and then administered TNF‐alpha had an aver‐
age of 5.34 cells per 1 cm2 and an average intensity of 3045. The
cortical neurons exposed to HBOT and then received LPS had an
average of 5.64 cells per 1 cm2 and an average intensity of 3192. A
One‐way ANOVA was conducted to analyze the effect of HBOT on
each condition. There was a statistically significant effect of HBOT
on viable cell count per 1 cm2 for all six conditions (F5,167 = 33.18,
P < 0.001). There was also a significant effect of HBOT on cell in‐
tensity for all six conditions (F5,182 = 22.29, P < 0.001).
Post hoc comparisons using Bonferroni's tests indicated the

2.6 | Statistics

mean number of cells per 1 cm2 for the control group was not signifi‐
cantly different than the HBOT group. However, the TNF‐alpha and

The data were evaluated using ANOVA followed by post hoc

LPS groups showed a significant reduction when compared to the

Bonferroni's tests. Statistical significance was preset at P < 0.05.

control group (P < 0.001, P < 0.001). HBOT preconditioning prior

Data are presented as mean ± SE from quintuplicates of each treat‐

to TNF‐alpha insult resulted in a significant increase in cell bodies

ment condition.

when compared to the TNF‐alpha group (P < 0.001). Similarly, the

F I G U R E 3 Primary cortical neuron cell
viability. Administration of Hyperbaric
oxygen therapy (HBOT) precondition
occurred 24 h prior to injury onset.
Primary rat neuronal cells (PRNCs)
cocultured with astrocytes were subjected
to HBOT for 90 min in the preconditioning
group. After the insult was introduced to
the PRNCs cocultured with astrocytes
for 24 h, the cell viability was analyzed by
Calcein‐AM staining. Cell counting was
performed and standardized per 1 cm2.
Intensity of signal was also calculated as
described in the materials and methods.
*P < 0.05, **P < 0.01, ***P < 0.001. The
scale bar corresponds to 20 μm

|
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F I G U R E 4 Mitochondrial transfer
to primary cortical neurons. Migration
of astrocyte mitochondria was tracked
using Mitotracker staining of astrocytes
prior to coculture with primary rat
neuronal cells (PRNCs). Cocultures were
subjected to the same preconditioning
setting as previously described. Transfer
of astrocyte mitochondria (cyan) was
quantified by counting the number PRNCs
containing cyan and dividing by the total
number of PRNCs marked with MAP2
(red). DAPI was utilized to mark PRNC
nuclei. *P < 0.05. **P < 0.01. The scale bar
corresponds to 20 μm

HBOT + LPS group demonstrated a significant increase in viable cell

prior to LPS insult had an average of 71.52% of neuronal cell bodies

bodies versus the LPS group (P < 0.001).

containing astrocytic mitochondria. There was a statistically signifi‐

Post hoc comparisons using Bonferroni's tests were also con‐
ducted for cell intensity. These results reiterated there was no sig‐

cant effect of HBOT on the percentage of astrocyte mitochondria in
neuronal cells for all six conditions (F5, 103 = 19.32, P < 0.001).

nificant difference in the means between the control group and the

Post hoc comparisons using Bonferroni's tests indicated the

HBOT preconditioning group. Again, there was a significant reduc‐

average percentage of neuronal cells containing astrocytic mito‐

tion of intensity in the TNF‐alpha and LPS groups when compared to

chondria for the control group was significantly less than the HBOT

the control group (P < 0.001, P < 0.001). When HBOT was adminis‐

preconditioning only group (P < 0.05). However, there was no sig‐

tered prior to TNF‐alpha it yielded a significantly increased intensity

nificant difference between the HBOT preconditioning only group

versus the TNF‐alpha group (P < 0.001). Also, HBOT preconditioning

with the TNF‐alpha and LPS groups. HBOT preconditioning prior to

prior to LPS administration also resulted in a significant increase in

TNF‐alpha insult resulted in a significant increase in astrocytic mi‐

intensity versus the LPS group (P < 0.01).

tochondria presence in neuronal cell bodies when compared to the
TNF‐alpha group (P < 0.01). Although the HBOT + LPS group failed

3.2 | Hyperbaric oxygen therapy stimulates
mitochondria transfer

to reach statistical significance compared to the LPS group, it dis‐
plays a similar trend to the TNF‐alpha and TNF‐alpha HBOT precon‐
ditioning comparison (Figure 4).

Mitochondria transfer was imaged using a scanning laser confocal mi‐
croscope (Figure 4). The percentage of neuronal cell bodies containing
astrocyte mitochondria was analyzed. The control cortical neurons
demonstrated an average of 21.25% of neuronal cell bodies containing

3.3 | Live imaging following HBOT demonstrates
mitochondrial transfer

astrocytic mitochondria. The HBOT group which received only HBOT

Live imaging was conducted using a scanning laser confocal micro‐

preconditioning and no insult had an average of 42.17% of neuronal

scope to capture images at 5‐minute intervals over a 30‐minute pe‐

cell bodies containing astrocytic mitochondria. Similarly, neurons that

riod (Figure 5). At acute period after HBOT initiation, live imaging

received TNF‐alpha and LPS treatment had an average of 44.23% and

revealed absence of Mitotracker‐labeled mitochondria at 0 minute

51.71% of neuronal cell bodies containing astrocytic mitochondria, re‐

but its presence at 5 minutes (Figure 5). Similarly, at delayed period

spectively. Cortical neurons exposed to HBOT preconditioning prior

following HBOT initiation between 15 minutes and 20 minutes, mi‐

to TNF‐alpha insult had an average of 68.21% of neuronal cell bodies

gration of Mitotracker‐labeled astrocytic mitochondria was visual‐

containing astrocytic mitochondria, while neurons exposed to HBOT

ized (Figure 5).

820
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F I G U R E 5 Live imaging of primary cortical neurons undergoing mitochondrial transfer. Rat E18 neuronal cells were harvested and
seeded in poly‐D‐lysine coated (100 μg/mL) 6‐well plates at 1.5 × 106 cells/well in Dulbecco's Modified Eagle Media high glucose with 1%
antibiotic/antimycotic for 24 h. The media was changed every 3 d, and the cells were subcultured at 90% confluency as needed. Twenty‐four
hours prior to the preconditioning, U87 astrocytes were stained with MitoTracker Deep Red FM (500 nmol/L) according to manufacturer's
protocol and seeded into coculture inserts at 0.5 × 106 cells/well. On the day of the experiment, rat E18 neuronal cells were stained with
MitoTracker Green FM (200 nmol/L) according to manufacturer's protocol. The neuronal cells were then cocultured with U87 astrocytes
for 3 h prior to Hyperbaric oxygen therapy (HBOT) administration. The cells were subjected to 70 min of HBOT at 2.5 ATA with 10 min
pressurization and depressurization at a rate of 0.07 atm/min for a total of 90 min. Directly following HBOT treatment, the cocultured
astrocytes were removed and the confocal z‐stacks live images were captured at 180× every 5 min for 30 min. Primary rat neuronal cell
(PRNC) mitochondria: Green; Astrocyte mitochondria: Red. The scale bar corresponds to 20 μm

4 | D I S CU S S I O N

TBI, providing a method to reduce the Inflammation‐plagued sec‐
ondary cell death.

The present study demonstrated the therapeutic effects of HBOT

We found a substantial increase of astrocytic mitochondria in the

preconditioning in protecting against the secondary cell death as‐

primary neurons particularly in the HBOT‐preconditioned groups via

sociated with cerebrovascular events, specifically stroke, and TBI.

Mitotracker labeling. Although there appears to be a natural trans‐

Primary neurons that were exposed to HBOT at 24 hours prior to

fer of mitochondria from astrocytes to neurons, as seen in the con‐

an inflammatory insult exhibited a significant reduction in cell death

trol cells grown under ambient cell culture condition, the presence

compared to the injury‐only groups. Further analysis revealed sub‐

of an injury to the neurons with exposure to TNF‐alpha or LPS sig‐

stantial increase of astrocytic mitochondria in the inflammation‐in‐

nificantly increased this astrocytic mitochondrial transfer (Figure 4).

sulted primary neurons, particularly in the HBOT‐preconditioned

Additionally, HBOT preconditioning under ambient condition facil‐

groups. Altogether, these results suggest HBOT reduces the del‐

itated the astrocytic mitochondrial transfer when compared to the

eterious inflammatory response, potentially through the transfer of

TNF‐alpha and LPS only groups (Figure 4). The combination of pre‐

mitochondria from astrocytes to neurons highlighting a highly inno‐

conditioning and inflammatory insult further increased the astrocytic

vative mechanistic pathway mediating the therapeutic efficacy of

mitochondrial transfer (Figure 4), suggesting that neurons primed

HBOT preconditioning.

with a surplus of astrocyte mitochondria were better metabolically

Mitochondrial dysfunction stands as a therapeutic target

equipped to survive an inflammatory insult compared to neurons with

in stroke and TBI due to its role in the secondary injury mecha‐

only a small number of astrocytic mitochondria. That astrocytic mito‐

nism.41,42 However, HBOT as a treatment for cerebrovascular

chondria may be more resistant to insults than neuronal mitochondria

diseases has yielded mixed results.14 The initiation of HBOT may

partially supports the notion that astrocytes in general do not easily

dictate the therapeutic, or detrimental, outcomes. To date, the

succumb to cell death after stroke compared to neurons.35,49

modality of HBOT preconditioning has been largely neglected;

Of equal translational importance, we also demonstrated that ad‐

HBOT's use as a prophylactic treatment for cerebrovascular dis‐

ministration of HBOT at 2.5 ATA for 90 minutes was well tolerated as

eases has only recently come into the spotlight for stroke and TBI

evidenced by maintained neuronal cell viability, highlighting the safety

research. Recent studies have postulated various mechanisms un‐

of the HBOT as a prophylactic treatment. Such initiation of HBOT

derlying HBOT's neuroprotective effects, including stabilizing the

before injury led to a significant neuroprotective effect (Figure 3). In

BBB and reducing inflammation.43-46 That BBB breakdown and in‐

addition, we found that the transfer of mitochondria occurred imme‐

flammatory response are closely associated with mitochondrial im‐

diately within a short period (ie, 5 minutes) following HBOT (Figure 6)

pairment provided the impetus in the present study to examine the

and persisted at least up to 20 minutes post‐HBOT (Figure 6). This ob‐

role of mitochondria as a therapeutic target of HBOT.47,48 Indeed,

servation of effective transfer of mitochondria even with acute HBOT

the transfer of mitochondria from astrocytes into neurons was ob‐

prior to injury supports the use of a short bout of HBOT at low ATA as

served after stroke. 34 Here, we showed that astrocytic mitochon‐

a powerful approach to induce neuroprotection, which circumvents

dria also transferred to neurons under ambient condition or when

reported adverse effects of prolonged HBOT at high ATA.50,51

exposed to an inflammatory insult, but such transfer was more ro‐

While not significantly detracting from our conclusions, there

bustly recognized when treated with HBOT prophylactically. These

are limitations to this investigation. The live imaging obtained

findings form the basis for prophylactic HBOT for individuals who

was conducted after completion of HBOT exposure, thereby pre‐

are at high risk of cerebrovascular events, specifically stroke and

venting us from accurately pinpointing the onset of mitochondria

|
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F I G U R E 6 Live imaging of primary cortical neurons undergoing mitochondrial transfer. Rat E18 neuronal cells were harvested and
seeded in poly‐D‐lysine coated (100 μg/mL) 6‐well plates at 1.5 × 106 cells/well in Dulbecco's Modified Eagle Media high glucose with 1%
antibiotic/antimycotic for 24 h. The media was changed every 3 d, and the cells were subcultured at 90% confluency as needed. Twenty‐four
hours prior to the preconditioning, U87 astrocytes were stained with MitoTracker Deep Red FM (500 nmol/L) according to manufacturer's
protocol and seeded into coculture inserts at 0.5 × 106 cells/well. On the day of the experiment, rat E18 neuronal cells were stained with
MitoTracker Green FM (200 nmol/L) according to manufacturer's protocol. The neuronal cells were then cocultured with U87 astrocytes
for 3 h prior to Hyperbaric oxygen therapy (HBOT) administration. The cells were subjected to 70 min of HBOT at 2.5 ATA with 10 min
pressurization and depressurization at a rate of 0.07 atm/min for a total of 90 min. Directly following HBOT treatment, the cocultured
astrocytes were removed and the confocal z‐stacks live images were captured at 180×. Primary rat neuronal cell (PRNC) mitochondria:
Green; Astrocyte mitochondria: Red. White arrows indicate the movement of astrocyte mitochondria into the PRNC during 5‐min intervals.
The scale bar corresponds to 20 μm
transfers. Moreover, although a single bout of HBOT was shown

Florida Morsani College of Medicine, Tampa, Florida, USA. All re‐

here as safe and effective in promoting neuroprotection, repeated

search materials, including data, reported in this study can be easily

short HBOT exposures may provide more stable and long‐lasting

accessed by contacting Dr. Cesario Borlongan.

functional outcomes considering the devastating neurological
deficits acutely and chronically after a cerebrovascular event. The
combination of pre‐ and postinjury HBOT will also warrant addi‐
tional studies. In order to translate this preconditioning paradigm

C O N FL I C T O F I N T E R E S T
The authors declare no conflicts of interest.

to the clinic, identification of a candidate population of individuals
who are at an increased risk of cerebrovascular injury will be key to
the successful enrollment of patients. The observed in vitro HBOT
results definitely will require validation in in vivo disease models.

ORCID
Cesario V. Borlongan

https://orcid.org/0000-0002-2966-9782

In the end, testing a variety of HBOT conditions in clinically rele‐
vant models are critical to achieving the optimal safe and effective
regimen of mitochondria transfer‐mediated neuroprotection. 52
Recent studies have established successful protocols for testing
HBOT in rodent models for both single and multiple treatments. 53
Due to prior FDA‐approved indications, HBOT has an established
infrastructure in clinics allowing for it to be quickly implemented
once treatments are optimized for humans.19,20
HBOT preconditioning poses as a prophylactic treatment for
sequestration of inflammation, which is a pathological condition
rampant in many cerebrovascular diseases. HBOT may be a leading
alternative treatment for TBI and stroke modalities as steers away
from invasive procedures such as exogenous cell transplantation fol‐
lowing a major cerebrovascular event.54 Mitochondrial transfer from
astrocytes to neurons is a potential primary mechanism of action of
HBOT to conferring neuroprotective effects against inflammation.
The ability to limit the severity of cerebrovascular injury in identified
at‐risk individuals may reduce the health burden and socioeconomic
load of these diseases on our healthcare system and economy.
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